COVID-19 vaccine

SK bioscience has been selected for Korea Disease Control and Prevention Agency's Priority Infectious Disease Pandemic Preparedness Rapid R&D Support Program to develop avian influenza vaccines.

Vaxart's Phase 2b trial of its oral COVID-19 vaccine candidate received a favorable review from the independent Data Safety Monitoring Board (DSMB).

Novavax has secured a $50 million milestone payment from Sanofi, triggered by progress in the Phase 2/3 clinical trial of its COVID-19 vaccine in children.

The FDA has lifted the clinical hold on Novavax's Phase 3 trial for its COVID-19/influenza combination and stand-alone influenza vaccine candidates.

The FDA has placed a clinical hold on Novavax's combination COVID-19 and influenza vaccine, along with its standalone influenza vaccine, following a serious adverse event report.